Trials / Completed
CompletedNCT04676178
A Study of PRA023 in Healthy Volunteers
A Phase 1, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetics Study of PRA023 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRA023 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRA023 | PRA023 |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2020-12-15
- Primary completion
- 2021-09-23
- Completion
- 2021-09-23
- First posted
- 2020-12-19
- Last updated
- 2024-01-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04676178. Inclusion in this directory is not an endorsement.